Recent News

AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

- AIC100 ICAM-1 Targeting CAR T Cell Therapy Recognized as Top Global Advance Made by Small Biotechnology Companies - NATICK, Mass., and LONDON, U.K. (November 17, 2023) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the [...]

AffyImmune Therapeutics to Present at 2023 Cell & Gene Meeting on the Mesa

NATICK, Mass., October 3, 2023 – AffyImmune Therapeutics, Inc., announced today that Matt Britz, Chief Operating Officer will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California and livestreamed globally. “We are looking forward to connecting with fellow leaders of cell [...]

ASCO 2023 Poster

Safety and early efficacy results of phase 1 study of affinity tuned and trackable AIC100 CAR T cells in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers ASCO 2023 Poster

AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

 Data show unprecedented CAR T patient response in ICAM-1 positive relapsed and/or refractory advanced poorly differentiated and anaplastic thyroid cancers Of the two patients evaluable for efficacy assessment at day 42 treated with an intermediate dose of CAR T cells, both experienced tumor reductions, with one achieving a partial response [...]

AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors

NATICK, Mass. (SEPTEMBER 29, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its Board of Directors. Mr. Forrester’s biotech experience [...]

Events

There are no events at this time.